Inhibition of cytokine production
AssigneeBTG International Limited
InventorsPeter Anthony Minter Eagles, Richard Qihao Zheng
Life of this patent
Estimating the term…
Loading patent…
AssigneeBTG International Limited
InventorsPeter Anthony Minter Eagles, Richard Qihao Zheng
Estimating the term…
The invention provides a ds-DNA oligomer which has from 25 to 150 base pairs, preferably 25 to 50 base pairs, and comprises the palindrome-containing sequence (one strand only shown) of formula (1): 5′B1. . . xN . . . B23′ (1) wherein B1 is ttgg or ccaa and B2 is correspondingly ccaa or ttgg and xN represents from 1 to 30 native nucleotides of substantially the native promoter sequence, together with the complementary strand, the oligomer being modified to make it resistant to degradation and denaturing in vivo. This oligomer or a vector carrying the palindrome-containing sequence (but not necessarily with the modification and not limited by any upper limit on the length of the oligomer sequence) can be used to inhibit transcription of the cytokine gene in vivo and is therefore useful in the therapy of diseases associated with undesired or excess production of cytokine.
A vector containing nucleotide sequence from a cytokine gene, said cytokine being selected from human interleukins and human TNF-alpha, said nucleotide sequence consisting of one or more copies of a double stranded oligomeric DNA sequence which is a substantially native sequence of the promoter region of the cytokine gene, said oligomeric sequence consisting of a length of 9 to 200 base pairs and containing a palindromic sequence of formula (1):
Dependencies are inferred from the claim text.